Gabor Veres, PhD

Gabor has 25+ years of experience in the development of cell and gene therapy products focusing mostly on genetic diseases. Currently the SVP of Translational Research at Mammoth Biosciences, he previously served as CSO of Vedere Bio II, Head of Gene Therapy at BioMarin Pharmaceuticals, Vice President of Translational Research at bluebird bio, Sangamo, etc. He initiated and coordinated multiple research programs using different gene delivery platforms to correct genetic and acquired diseases and cancer. He led several programs from discovery, pre-clinical research and through late-stage development, including approved gene therapy treatment for CALD (SKYSONA), β-thalassemia (ZYNTEGLO), sickle cell disease (LYFGENIA), multiple myeloma (ABECMA), and hemophilia A (ROCTAVIAN).